1. Characterization and Therapeutic Effect of a pH Stimuli Responsive Polymeric Nanoformulation for Controlled Drug Release
- Author
-
Maria Victoria Cano-Cortes, Rosario M. Sánchez-Martín, Jose Antonio Laz-Ruiz, Juan J. Díaz-Mochón, [Cano-Cortes,MV, Laz-Ruiz,JA, Diaz-Mochon,JJ, Sanchez-Martin,RM] GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, Spain. [Cano-Cortes,MV, Sanchez-Martin,RM] Department of Medicinal & Organic Chemistry, Excellence Research Unit of 'Chemistry Applied to Biomedicine and the Environment', Faculty of Pharmacy, University of Granada, Granada, Spain. [Cano-Cortes,MV, Sanchez-Martin,RM] Biosanitary Research Institute of Granada (ibs. GRANADA), University Hospital, Granada, Spain., and This research was funded by the Spanish Ministry of Economy and Competitiveness (MINECO), grant number BIO2016-80519 and the Health Institute Carlos III (ISCIII), grant number DTS18/00121 and the Andalusian Regional Government, grant number PAIDI-TC-PVT-PSETC-2.0.
- Subjects
Drug ,Polymers and Plastics ,Cancer therapy ,Concentración de iones de hidrógeno ,media_common.quotation_subject ,Covalent drug conjugation ,Therapeutic nanodevice ,02 engineering and technology ,Pharmacology ,01 natural sciences ,Article ,Polymeric nanoparticles ,lcsh:QD241-441 ,Therapeutic index ,lcsh:Organic chemistry ,Anatomy::Cells::Cells, Cultured::Cell Line [Medical Subject Headings] ,Controlled drug deliver ,Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Toxicity Tests::Inhibitory Concentration 50 [Medical Subject Headings] ,Nanodevice ,IC50 ,Phenomena and Processes::Chemical Phenomena::Hydrogen-Ion Concentration [Medical Subject Headings] ,covalent drug conjugation ,Technology and Food and Beverages::Technology, Industry, and Agriculture::Manufactured Materials::Nanostructures::Nanoparticles [Medical Subject Headings] ,media_common ,therapeutic nanodevice ,Controlled drug delivery ,Phenomena and Processes::Genetic Phenomena::Genetic Processes::DNA Damage [Medical Subject Headings] ,010405 organic chemistry ,Chemistry ,Therapeutic effect ,Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents [Medical Subject Headings] ,Nanopartículas ,Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Drug Therapy::Drug Delivery Systems::Delayed-Action Preparations [Medical Subject Headings] ,General Chemistry ,021001 nanoscience & nanotechnology ,Controlled release ,controlled drug delivery ,In vitro ,0104 chemical sciences ,polymeric nanoparticles ,Cancer cell ,Concentración 50 Inhibidora ,cancer therapy ,Chemicals and Drugs::Organic Chemicals::Alcohols::Glycols::Ethylene Glycols::Polyethylene Glycols [Medical Subject Headings] ,0210 nano-technology - Abstract
Despite the large number of polymeric nanodelivery systems that have been recently developed, there is still room for improvement in terms of therapeutic efficiency. Most reported nanodevices for controlled release are based on drug encapsulation, which can lead to undesired drug leakage with a consequent reduction in efficacy and an increase in systemic toxicity. Herein, we present a strategy for covalent drug conjugation to the nanodevice to overcome this drawback. In particular, we characterize and evaluate an effective therapeutic polymeric PEGylated nanosystem for controlled pH-sensitive drug release on a breast cancer (MDA-MB-231) and two lung cancer (A549 and H520) cell lines. A significant reduction in the required drug dose to reach its half maximal inhibitory concentration (IC50 value) was achieved by conjugation of the drug to the nanoparticles, which leads to an improvement in the therapeutic index by increasing the efficiency. The genotoxic effect of this nanodevice in cancer cells was confirmed by nucleus histone H2AX specific immunostaining. In summary, we successfully characterized and validated a pH responsive therapeutic polymeric nanodevice in vitro for controlled anticancer drug release., Spanish Ministry of Economy and Competitiveness (MINECO) BIO2016-80519, Health Institute Carlos III (ISCIII) DTS18/00121, Andalusian Regional Government PAIDI-TC-PVT-PSETC-2.0
- Published
- 2020